Volume 6, Issue 1 , Pages 38-43, January 2005
Drug-eluting stents for the treatment of in-stent restenosis:
A clinical review
Abstract
Treatment of in-stent restenosis (ISR) remains problematic despite the widespread application of drug-eluting stents (DES). Challenging lesion cohorts such as diffuse ISR and restenosis after failed intracoronary radiation therapy (IRT) maybe best treated with DES. The overall benefit of DES appears inferior to their utility in treating de novo coronary lesions. Randomised trials comparing DES and IRT will soon be available to determine the optimal therapy for ISR. The challenge to treat ISR in the DES era is the next frontier of interventional cardiology.
Keywords: In-stent restenosis, Drug-eluting stents, Sirolimus, Paclitaxel, Intracoronary radiation therapy
To access this article, please choose from the options below
PII: S1553-8389(05)00034-5
doi:10.1016/j.carrev.2005.04.003
© 2005 Elsevier Inc. All rights reserved.
Volume 6, Issue 1 , Pages 38-43, January 2005
